Vyant Bio, Inc.

Good morning and welcome to the ViantBio year-end 2021 results conference call and webcast. Today, March 30, 2022, the company issued a press release summarizing results for the year-end 2021 and filed its Form 10-K. Today's discussion will provide an overview of activities in the fourth quarter and full year 2021, is being recorded, and a replay of the webcast will be available on the ViantBio website following today's call. Alternatively, the link can be sent to you by contacting IR at ViantBio.com. All participants on this call will be in a listen-only mode during the presentation. The presentation will be followed by a question-and-answer session. At this time, I would now like to turn the conference over to Jay Roberts, Chief Executive Officer of ViantBio. Please go ahead, sir.

Thank you, operator, and thank you all for joining the Buy and Buy Investor Conference call and webcast of the year ended December 31st, 2021. While we had planned to file our SEC reports and our press release sooner, the SEC system was experiencing a global connectivity issue for a short period of time, so we apologize for that delay. Now that the merger and the related integration activities are substantially complete, we spent the fourth quarter fully focused on executing our business plan. It is also a great pleasure to speak with you today to share our enthusiasm and to give you some insight into how we envision the near-term future of Buy and Bio. Additionally, we're going to present financial results for the year ended 2021. On the call with me today is Buy and Bio's Chief Financial Officer, Angela Frenz, and our Chief Science Officer, Dr. Robert Fermot. Following the Safe Harbor Statement, Dr. Fermot and I will provide a strategic overview and update on recent scientific and corporate developments and the vision ahead. Then Andy will take us through a brief financial update to discuss key accounting matters for the 2021 periods just ended. I will make some closing remarks, and then we will open up the lines for questions for Andy, Bob, and me. I will now turn the call over to our CFO, Andy LaFrance.

Thank you, Jay, and welcome to all. We would like to remind everyone that various comments about future expectations plans and prospects constitute forward-looking statements for purposes of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Line Bio cautions that these forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially from those indicated, including risks described in the company's filings with the Securities and Exchange Commission. Any forward-looking statements made on this conference call speak only of today's date, Wednesday, March 30th, 2022, and ViantBio does not intend to update any of these forward-looking statements to reflect events or circumstances that would occur after today's date. This conference call is also being recorded for audio rebroadcast on ViantBio's website at www.viantbio.com. With that, I'd like to turn the call back over to Jay Roberts. Jay?